Monotherapy IVIG Gamunex-C for HMG-CoA Reductase Auto-Antibody Positive Necrotizing Myopathy Treatment (The MIGHT Trial)

Overview

This is a phase 2, pilot, randomized, placebo-controlled trial of Gamunex-C IVIG as mono-therapy for HMGCoA reductase auto-antibody positive (HMGCR) necrotizing myopathy. The trial will test the feasibility and initial efficacy of Gamunex-C IVIG mono-therapy in HMGCR necrotizing myopathy.

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
  • Study Primary Completion Date: July 2022

Detailed Description

This is a phase 2, double-blinded, randomized, placebo-controlled, multi-center trial of Gamunex-C IVIG as mono-therapy for HMGCR necrotizing myopathy. Up to 10 treatment-naïve patients will be enrolled and randomized to receive either Gamunex-C IVIG dosed at 2g/kg or placebo at week 0 and week 4. The primary efficacy outcome is the percentage of patients at week 8 with at least minimal improvement per the 2016 ACR/EULAR myositis clinical response criteria.

Interventions

  • Drug: Gamunex-C
    • Gamunex-C IVIG will be given at week 0 and week 4
  • Drug: Albumin
    • 1% albumin solution dosed at equivalent volume to the corresponding weight-based Gamunex-C IVIG dose will be given at week 0 and week 4

Arms, Groups and Cohorts

  • Experimental: Gamunex-C IVIG
    • Gamunex-C IVIG dosed at 2g/kg will be given on week 0 and week 4.
  • Placebo Comparator: Placebo
    • Albumin in a 1% solution at an equivalent volume to the corresponding Gamunex-C IVIG dose will be given at week 0 and week 4.

Clinical Trial Outcome Measures

Primary Measures

  • ACR/EULAR 2016 Clinical Response Criteria for Myositis
    • Time Frame: week 8
    • The percentage of patients in each arm with at least a minimal response

Secondary Measures

  • Manual Muscle Strength Testing (MMT-8) score
    • Time Frame: week 8
    • Manual muscle strength testing in 8 muscle groups will be scored
  • ACR/EULAR Clinical Response Criteria for Myositis Total Improvement Score
    • Time Frame: week 8
    • The total improvement score based on ACR/EULAR 2016 criteria will be calculated
  • HMG-CoA Reductase Auto-antibody titer level
    • Time Frame: week 8
    • Autoantibody titer level will be assessed
  • Creatine kinase
    • Time Frame: week 8
    • Serum creatine kinase level will be measured
  • Number of patients screened to achieve planned enrollment
    • Time Frame: 2 years
  • Number of days needed to enroll planned sample
    • Time Frame: 2 years
  • Percentage of enrolled patients completing all primary and secondary measures
    • Time Frame: 2 years

Participating in This Clinical Trial

Inclusion Criteria

A subject must meet all of the following inclusion criteria at screening to be eligible for participation in this study:

  • Anti-HMGCR positive. Patients will be screened by commercially-available ELISA.
  • Age ≥ 18 years
  • Demonstrable proximal muscle weakness: score of <135 on the Proximal Manual Muscle Strength Testing 8-Muscle Group Assessment (MMT-8) (range 0-160).
  • Serum creatinine kinase (CK) more than 5 times the upper limit of normal
  • Muscle biopsy will not be required for eligibility in order to minimize the time to enrollment and initiation of treatment. Muscle biopsy will be obtained whenever possible as part of the standard of care.
  • Subjects must be willing and able to provide written informed consent.

Exclusion Criteria

A subject meeting any of the following exclusion criteria at screening is NOT eligible for participation in this study:

  • Disease duration greater than 36 months.
  • Currently taking glucocorticoids.
  • Participants will need to be tapered off all glucocorticoids by their treating physician over an interval deemed appropriate, and be free of steroid use for at least 14 days prior to the time of study screening in order to be eligible.
  • Exposure to immunoglobulin treatment (IV, IM, or SubQ) in the prior 3 months
  • Exposure to plasma exchange (PEX) in the prior 3 months
  • Exposure to other immunosuppressive medications (e.g. methotrexate, leflunomide, azathioprine, mycophenolate mofetil) in the prior 6 months
  • Exposure to rituximab or any monoclonal antibody in the prior 12 months
  • Exposure to a statin in the prior 3 months
  • History of dermatomyositis rash (either biopsy-proven, or history of photosensitive rash).
  • Presence of respiratory or swallowing dysfunction due to HMGCR myopathy
  • Inadequate venous access
  • History of anaphylactic reactions or severe reactions to any blood-derived product
  • History of intolerance to any component of the IP
  • History of thrombotic complication to polyclonal IVIG therapy
  • History of pulmonary embolism or deep venous thromboembolism
  • History of hyperviscosity or hypercoagulable state
  • History of myocardial infarction or stroke in the last 12 months
  • Currently receiving anti-coagulation therapy (vitamin K antagonists, non-vitamin K oral anticoagulants [e.g. dabigatran, rivaroxaban, apixaban], parenteral anticoagulants [e.g fondaparinux]. Note that oral anti-platelet agents are allowed (e.g. aspirin, clopidogrel, ticodipine).
  • Females of child-bearing potential who are pregnant, have a positive serum pregnancy test (human chorionic gonadotropin [HCG]-based assay), breastfeeding, or are unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device or intrauterine system, condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence*) throughout the study.

* True abstinence: When this is in line with the preferred and usual lifestyle of the subject. (Periodic abstinence [e.g., calendar, ovulation, symptothermal, post-ovulation methods], declaration of abstinence for the duration of a trial, and withdrawal are not acceptable methods of contraception.)

  • Renal impairment (i.e., serum creatinine exceeds more than 1.5 times the upper limit of normal [ULN] for the expected normal range for the testing laboratory)
  • Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceeding more than 2.5 times the ULN for the expected normal range for the testing laboratory.
  • Hemoglobin level <9 g/dL
  • Known Immunoglobulin A (IgA) deficiency and anti-IgA serum antibodies
  • History of chronic alcoholism or illicit drug abuse (addiction) in the prior 12 months
  • Active psychiatric illness that interferes with compliance or communication with healthcare personnel
  • Currently receiving, or having received, within 1 month prior any investigational medicinal product or device. In the case of an investigational medicinal product trial, at least five half- lives (if known) must have elapsed prior to Screening.
  • Any medical condition which makes the clinical trial participation unadvisable or which is likely to interfere with the evaluation of the study treatment and/or the satisfactory conduct of the clinical trial according to the investigator's judgment. Any factor that in the opinion of the investigator would compromise the ability of the subject to complete the trial
  • Weight > 120kg. Individuals weighing >100kg and ≤120kg will be eligible at the discretion of the investigators.
  • History of angina pectoris or transient ischemic attack (TIA) in the last 12 months
  • Wells Criteria Score for DVT of 2 or more at the time of screening.
  • Wells Criteria Score for PE of 4 or more at the time of screening.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 120 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • University of Washington
  • Collaborator
    • Grifols Biologicals, LLC
  • Provider of Information About this Clinical Study
    • Principal Investigator: James S. Andrews, Assistant Professor, School of Medicine: Rheumatology – University of Washington
  • Overall Official(s)
    • James S Andrews, MD, Principal Investigator, University of Washington
  • Overall Contact(s)
    • Leslie Thorn, 206-295-4425, lazthorn@uw.edu

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.